[Acneiform eruption from epidermal growth factor receptor inhibitors]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• The development of targeted cancer therapies aims to improve efficacy and reduce toxicity compared to traditional chemotherapy.
• Epidermal growth factor receptor (EGFR) inhibitors represent a novel class of anti-cancer drugs with a more specific action against neoplastic cells.

Observation:

• Skin eruptions are a common adverse effect of EGFR inhibitors.
• These eruptions are linked to the drug's direct impact on epidermal homeostasis and the pilosebaceous unit.
• Recent literature highlights various cases of cutaneous toxicity associated with EGFR inhibitor therapy.

Findings:

• This report details three cases of acneiform eruptions.
• The eruptions were attributed to distinct drugs within the EGFR inhibitor family: cetuximab, gefitinib, and erlotinib.

Implications:

• Understanding and managing skin toxicities is crucial for patients undergoing EGFR inhibitor treatment.
• These findings emphasize the need for dermatological monitoring in oncology patients receiving these targeted therapies.
• Further research into mitigating EGFR inhibitor-induced dermatological side effects may improve patient compliance and treatment outcomes.